Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1977 1
1978 3
1980 1
1981 2
1982 4
1983 2
1984 2
1985 2
1986 3
1987 3
1988 6
1989 7
1990 6
1991 2
1992 2
1993 9
1994 5
1995 5
1996 3
1997 6
1998 7
1999 5
2000 4
2001 5
2002 3
2003 4
2004 4
2005 5
2006 6
2007 8
2008 16
2009 12
2010 9
2011 12
2012 11
2013 14
2014 15
2015 16
2016 26
2017 20
2018 9
2019 11
2020 11
2021 26
2022 19
2023 16
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

337 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Neif Antonio J Jr, Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD. Bajorin DF, et al. Among authors: peer a. N Engl J Med. 2021 Jun 3;384(22):2102-2114. doi: 10.1056/NEJMoa2034442. N Engl J Med. 2021. PMID: 34077643 Free PMC article. Clinical Trial.
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoa T, Merchan JR, Winquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators. Motzer R, et al. Among authors: peer a. N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13. N Engl J Med. 2021. PMID: 33616314 Clinical Trial.
Single-cell brain organoid screening identifies developmental defects in autism.
Li C, Fleck JS, Martins-Costa C, Burkard TR, Themann J, Stuempflen M, Peer AM, Vertesy Á, Littleboy JB, Esk C, Elling U, Kasprian G, Corsini NS, Treutlein B, Knoblich JA. Li C, et al. Among authors: peer am. Nature. 2023 Sep;621(7978):373-380. doi: 10.1038/s41586-023-06473-y. Epub 2023 Sep 13. Nature. 2023. PMID: 37704762 Free PMC article.
Reply by Authors.
Lifshitz K, Ber Y, Shenhar C, Nillson J, Peer A, Rosenbaum E, Baniel J, Kedar D, Ben Zadok OI, Margel D. Lifshitz K, et al. Among authors: peer a. J Urol. 2021 Oct;206(4):959. doi: 10.1097/JU.0000000000001879.03. Epub 2021 Jul 14. J Urol. 2021. PMID: 34259539 No abstract available.
Reply By Authors.
Margel D, Peer A, Ber Y, Shavit-Grievink L, Tabachnik T, Sela S, Witberg G, Baniel J, Kedar D, Duivenvoorden WCM, Rosenbaum E, Pinthus JH. Margel D, et al. Among authors: peer a. J Urol. 2019 Dec;202(6):1208. doi: 10.1097/01.JU.0000581976.09106.a4. Epub 2019 Sep 5. J Urol. 2019. PMID: 31487209 No abstract available.
Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis.
Rouvinov K, Levanon E, Peer A, Sarfaty M, Sarid D, Neiman V, Grikshtas E, Rosenbaum E, Kushnir I, Talmor B, Friger M, Zarbiv Y, Gez E, Dresler H, Shalata W, Meirovitz A, Shrem NS, Yakobson A, Mermershtain W, Keizman D. Rouvinov K, et al. Among authors: peer a. Front Oncol. 2023 May 24;13:1151701. doi: 10.3389/fonc.2023.1151701. eCollection 2023. Front Oncol. 2023. PMID: 37293597 Free PMC article.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Alekseev B, Rha SY, Merchan J, Goh JC, Lalani AA, De Giorgi U, Melichar B, Hong SH, Gurney H, Méndez-Vidal MJ, Kopyltsov E, Tjulandin S, Gordoa TA, Kozlov V, Alyasova A, Winquist E, Maroto P, Kim M, Peer A, Procopio G, Takagi T, Wong S, Bedke J, Schmidinger M, Rodriguez-Lopez K, Burgents J, He C, Okpara CE, McKenzie J, Choueiri TK; CLEAR Trial Investigators. Motzer RJ, et al. Among authors: peer a. J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16. J Clin Oncol. 2024. PMID: 38227898 Free article. Clinical Trial.
Activity, Plan, and Goal Recognition: A Review.
Van-Horenbeke FA, Peer A. Van-Horenbeke FA, et al. Among authors: peer a. Front Robot AI. 2021 May 10;8:643010. doi: 10.3389/frobt.2021.643010. eCollection 2021. Front Robot AI. 2021. PMID: 34041274 Free PMC article. Review.
337 results